Cell Therapy and Gene Therapy Disease Markets, 2023-2029

Table of Contents

Chapter 1: Executive Summary

Overview

Scope and Methodology

Market Overview and Potential

• Figure 1-1: Global Cell and Gene Therapy Market, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
• Table 1-1: Global Cell and Gene Therapy Market, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)

 

Chapter 2: Introduction to Cell and Gene Therapy

Introduction

• Table 2-1: Total Numbers of Approved Cell, Gene, & RNA Therapies, by Type, Q4 2022-Q1 2024 (ending March 2024), Global (count, %)
• Figure 2-1: Share of Total Global Numbers of Approved Cell, Gene, & RNA Therapies, by Type, March 2024 (%)

Cell Therapy

• CAR T
• Stem Cells
• Adult Stem Cells
• Human Embryonic Stem Cells
• Table 2-2: Adult vs. Embryonic Stem Cells

Gene Therapy

• Table 2-3: Somatic vs. Germ Line Gene Therapy

Viral Vector System and New Developments

• Table 2-4: Selected Examples of Viruses in Gene Therapy
• Figure 2-2: Estimated Viral Vector Use in Commercialized Cell and Gene Therapies, by Type, 2022 (%)

Non-viral Systems for Transporting Genes

Gene Editing

Cell and Gene Therapy: Characteristics

• Table 2-5: Cell Therapy vs Gene Therapy

Staffing

Manufacturing Process for CAR-T

Leukapheresis

Activation

Transduction

Expansion

Cell and Gene Therapy Manufacturing Processes

• Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
• Figure 2-3: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)

Cost

Reimbursement

Logistics

Mergers and Acquisitions

• Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market

Deals, Agreements, and Collaborations

Regulatory Developments

Fast Track

Orphan Drug

Breakthrough Therapy

Accelerated Approval

Priority Review

• Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy, by Select Country

Individualized Gene Therapy Approval Process

Pipeline, Development Overview

Pipeline, Development Progress

• Table 2-9: Global Cell, Gene, & RNA Therapy Clinical Trial Growth (pre-clinical I through phase III), Q4 2022-Q1 2024 ($ millions, %)
• Figure 2-4: Global Cell, Gene, & RNA Therapy Development Progress (pre-clinical through phase III), as of March 2024
• Table 2-10: Global Gene Therapy Pipeline, by Phase, Q4 ’22-Q1 ’24 (count, %)
• Figure 2-5: Global Gene Therapy Pipeline Shares by Phase, Q1 ’24 (%)

Pipeline by Condition and Therapeutic Area

• Table 2-11: Global Cell, Gene, & RNA Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other), Q4 ’22-Q1 ’24 (count, %)
• Figure 2-6: Global Gene Therapy Pipeline Shares, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q1 ’24 (%)
• Table 2-12: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 ’22-Q1 ’24 (count, %)
• Table 2-13: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease (Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa; Other), Q4 ’22-Q1 ’24 (count, %)
• Figure 2-7: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease (Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa), Q4 ’22-Q1 ’24 (%)
• Table 2-14: Global Non-GM Cell Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary  [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 ’22-Q1 ’24 (count, %)
• Table 2-15: Global Non-GM Cell Therapy Pipeline, by Condition/Disease (Alzheimer’s disease; Arthritis, osteo; Cancer, brain; Cancer, breast; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lung, non-small cell; Cancer, melanoma; Cancer, ovarian; Cancer, solid, unspecified; Cancer, unspecified; COVID-19 complications; Diabetes, Type 1; Graft-versus-host disease; Heart failure; Hepatic dysfunction, unspecified; Infarction, myocardial; Ischemia, cerebral; Parkinson’s disease; Respiratory distress syndrome, acute; Spinal cord injury), Q4 ’22-Q1 ’24 (count, %)
• Table 2-16: Global Non-GM Cell Therapy Pipeline, by Rare Disease Targeted (Amyotrophic lateral sclerosis; Anal fistula; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lymphoma, non-Hodgkin’s; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Dystrophy, Duchenne’s muscular; Epidermolysis bullosa; Fibrosis, pulmonary, idiopathic; Graft-versus-host disease; Huntington’s disease; Myelodysplastic syndrome; Respiratory distress syndrome, acute; Retinitis pigmentosa; Spinal cord injury; Thalassemia), Q4 ’22-Q1 ’24 (count, %)
• Table 2-17: Global RNA Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Antiparasitic, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary  [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 ’22-Q1 ’24 (count, %)
• Table 2-18: Global RNA Therapy Pipeline, by Rare Disease Targeted (Amyotrophic lateral sclerosis; Cancer, liver; Cancer, ovarian; Cancer, pancreatic; Cystic fibrosis; Dementia, frontotemporal;  Dystrophy, Duchenne’s muscular; Dystrophy, myotonic muscular; Fibrosis, pulmonary, idiopathic; Huntington’s disease; Infection, malaria prophylaxis; Infection, rabies prophylaxis; Primary ciliary dyskinesia; Respiratory distress syndrome, acute), Q4 ’22-Q1 ’24 (count, %)

Phase III Development

• Table 2-19: Phase III Development – Cell and Gene Therapies, Select Projects

End Users

Hospitals

Research Institutes

Wound Care Centers

Cancer Centers

 

Chapter 3: Cell and Gene Therapy Markets in Oncology

Overview

Biochemistry of Cancer Cells

Causes of Cancer Growth

Environmental Factors, DNA, RNA

• Table 3-1: Virus Association with Human Cancer

Cellular Oncogenes

Tumor Suppressor Genes

Global Cancer Burden

• Figure 3-1: Estimated Number of New Cancer Cases from 2020 to 2040, Both Sexes, Age 0-85+, All Cancers
• Figure 3-2: Incidence of Cancer, by Type (Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid), 2020
• Figure 3-3: Worldwide Distribution of Cancer Incidence, by Type (Brest, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Other Cancers), 2020

Market Outlook

• Table 3-2: Cell, Gene, & RNA Therapy Markets in Oncology, 2023-2029 ($ millions)
• Figure 3-4: Cell, Gene, & RNA Therapy Markets in Oncology, 2023-2029 ($ millions)

Principal Products

Abecma

APCeden

Breyanzi

Carvykti

CreaVax-RCC

Delytact

Gendicine

Imlygic

Immuncell-LC

Kymriah

Provenge

Tecartus

Yescarta

• Table 3-3: Cell and Gene Therapy in Oncology

Trends in Research and Development

Phase III Development

• Table 3-4: Select Oncology Phase III Cell, Gene, & RNA Therapy Developments, through March 2024

Market Breakdown of Cell and Gene Therapies

• Table 3-5: Oncology Cell and Gene Therapy Markets, by Product Type (CAR-T, Cell Immunotherapy, Gene Therapy), Estimated 2023 and Projected 2029 ($ millions)
• Figure 3-5: Oncology Cell and Gene Therapy Market Distribution, by Product Type (CAR-T, Cell Immunotherapy, Gene Therapy), 2023 (%)

Oncology Cell and Gene Therapy Market by Cancer Type

• Table 3-6: Oncology Cell, Gene, & RNA Therapy Market, by Cancer Type (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer,  Undefined Blood Cancer, Other Cancers), Estimated 2023 and Projected 2029 ($ millions)
• Table 3-7: Oncology Cell, Gene, & RNA Therapy Market, by General Indication (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers), 2023 (%)
• Figure 3-6: Oncology Cell, Gene, & RNA Therapy Market, by General Indication (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers), 2023 (%)

Regional Market Summary

• Table 3-8: Oncology Cell and Gene Therapy Market, by Country/Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
• Figure 3-7: Oncology Cell and Gene Therapy Market Summary, by Geographic Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

• Table 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
• Figure: 3-8: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Estimated 2023 (%)

 

Chapter 4: Cell and Gene Therapy Markets in Neurological-Related Disorders

Overview

Market Outlook

• Table 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2023-2029 ($ millions)
• Figure 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2023-2029 ($ millions)

Principal Products

Amvuttra

Libmeldy/ Lenmeldy

NeuroNata-R

Onpattro

SKYSONA

Spinraza

Stemirac

Wainua

Zolgensma

• Table 4-2: Cell, Gene, and RNA Therapy in Neurological Diseases and Disorders

Trends in Research and Development

Phase III Development

• Table 4-3: Select Neurological Phase III Cell and Gene Therapy Developments, through March 2024

Market Breakdown of Cell and Gene Therapies

• Table 4-4: Neurological Conditions Cell and Gene Therapy Markets, by Product Type (Cell Therapy, Gene Therapy, RNA/Antisense Therapy), Estimated 2023 and Projected 2029 ($ millions)
• Figure 4-2: Neurological Conditions Cell, Gene, & RNA Therapy Market Distribution, by Product Type, 2023 (%)

Regional Market Summary

• Table 4-5: Neurological Conditions Cell and Gene Therapy Market, by Country/Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
• Figure 4-3: Neurological Conditions Cell, Gene, & RNA Therapy Market Summary, by Geographic Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

• Table 4-6: Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
• Figure 4-4: Neurological Conditions Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2023 ($ millions)

 

Chapter 5: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders

Overview

Market Outlook

• Table 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2023-2029 ($ millions)
• Figure 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2023-2029 ($ millions)

Principal Products

AlloStem

Amondys

BIO4

Carticel

Cartiform

CartiLife

Cartistem

Chondron

Elevidys

Exondys

JACC

MACI

Ortho-ACI and Ortho-ATI

Ossron

Osteocel and Osteoplus

Spherox

Trinity Elite and Trinity Evolution

Vyondys

• Table 5-2: Cell and Gene Therapies in Musculoskeletal Diseases and Disorders

Trends in Research and Development

Phase III Development

• Table 5-3: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through March 2024

Market Breakdown of Cell and Gene Therapies

• Table 5-4: Musculoskeletal Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2023 and Projected 2029 ($ millions)

Musculoskeletal Cell and Gene Therapy Market by Indication

• Table 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication (Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others [Tendon Damage, Osteoarthritis]), Estimated 2023 and Projected 2029 ($ millions)
• Figure 5-2: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication (Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others [Tendon Damage, Osteoarthritis]), Estimated 2023 (%)

Regional Market Summary

• Figure 5-3: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region (Europe, United States, South Korea, ROW), Estimated 2023 (%)
• Table 5-6: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region (Europe, United States, South Korea, ROW), Estimated 2023 and Projected 2029 ($ millions)
• Figure: 5-4: Musculoskeletal Cell and Gene Therapy Market Summary, by Geographic Region (Europe, United States, South Korea, ROW), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

• Table 5-7: Musculoskeletal Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
• Figure 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2023 (%)

 

Chapter 6: Cell and Gene Therapy Markets in Dermatology

Overview

• Table 6-1: Wound Prevalence, by Type (Skin Ulcers: Pressure Injuries, Venous Statis Ulcers, Diabetic Ulcers and Burns: Outpatient Burns, Hospitalized Burns, and Medically Treated Burns)

Market Outlook

• Figure 6-1: Cell and Gene Therapy Markets in Dermatology, 2023-2029 ($ millions)

Principal Products

Adipocel

Apligraf

CureSkin

Dermagraft

Epicel

Grafix

Holoderm

Kaloderm

KeraHeal/KeraHeal-Allo

LaViv

Orcel

Quencell

RECELL

Rosmir

Stempeutics/Cutisera

StrataGraft

Stravix

TransCyte

Vyjuvek

• Table 6-2: Cell and Gene Therapy in Dermatological Diseases and Disorders

Trends in Research and Development

Phase III Development

• Table 6-3: Select Dermatology Phase III Cell and Gene Therapy Developments, through March 2024

Market Breakdown of Cell and Gene Therapies

• Table 6-4: Dermatology Cell and Gene Therapy Markets, by Product Type (Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy), Estimated 2023 and Projected 2029 ($ millions)
• Figure 6-2: Dermatology Cell and Gene Therapy Market Distribution, by Product Type (Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy), 2023 (%)

Dermatology Cell and Gene Therapy Market by Indication

Regional Market Summary

• Table 6-5: Dermatology Cell and Gene Therapy Market, by Country/Region (Asia, Europe, United States, Other Countries), Estimated 2023, Projected 2029 ($ millions)
• Figure: 6-3: Dermatology Cell and Gene Therapy Market Summary, by Geographic Region (Asia, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

• Table 6-6: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
• Figure: 6-4: Dermatology Cell and Gene Therapy Market Share, by Company, Estimated 2023 (%)

 

Chapter 7: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders

Overview

Cardiovascular Disease

Selected Blood Disorders

Market Outlook

• Table 7-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2023-2029 ($ millions)
• Figure 7-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2023-2029 ($ millions)

Principal Products

Collategene

Hearticellgram

HeartSheet

Leqvio

Neovasculgen

Stempeucel

Zynteglo

• Table 7-2: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders

Phase III Development

• Table 7-3: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through Mar 2023

Market Breakdown of Cell, Gene, and RNA Therapies

• Table 7-4: Cardiovascular and Blood Disorders Cell, Gene, & RNA Therapy Markets, by Product Type (Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies), Estimated 2023 and Projected 2029 ($ millions)
• Figure 7-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution, by Product Type (Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies), 2023 (%)

Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication

• Table 7-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by General Indication (Blood, Cardiac, Hypercholesterolemia, Vascular), Estimated 2023 and Projected 2029 ($ millions)

Regional Market Summary

• Table 7-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by Country/Region (APAC, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)
• Figure 7-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary, by Geographic Region (APAC, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

 

Chapter 8: Cell and Gene Therapy Markets in Other Conditions

Overview

Market Outlook

• Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2023-2029 ($ millions)
• Table 8-1: Cell and Gene Therapy Markets in Other Conditions, 2023-2029 ($ millions)

Principal Products

Alofisel

Cupistem

Givlaari

Glybera

Holoclar

Luxturna

Oxlumo

Rethymic

Strimvelis

Temcell/Prochymal/Ryoncil

• Table 8-2: Cell and Gene Therapy in Other Diseases and Disorders

Trends in Research and Development

Market Breakdown of Cell and Gene Therapies

• Table 8-3: Other Conditions Cell and Gene Therapy Markets, by Product Type (Cell-based Gene Therapy; RNA, Antisense Etc; Stem Cell & Other Cell Therapy; Other Gene Therapy), Estimated 2023 and Projected 2029 ($ millions)
• Figure 8-2: Other Conditions Cell and Gene Therapy Market Distribution, by Product Type (Cell-based Gene Therapy; RNA, Antisense Etc; Stem Cell & Other Cell Therapy; Other Gene Therapy), 2023 (%)

Regional Market Summary

• Table 8-4: Other Conditions Cell and Gene Therapy Market, by Country/Region (Europe, Japan, South Korea, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
• Figure 8-3: Other Conditions Cell and Gene Therapy Market Summary, by Geographic Region (Europe, Japan, South Korea, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)

Competitor Summary

 

Chapter 9: Cell and Gene Therapy Market Review

Market Influences

Global Demographics

• Table 9-1: Global Population, through 2050 (population in millions)
• Aging Population
• Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Cost Containment

• Table 9-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies

Cell and Gene Therapy and Viral Vector Shortages

Global Market Summary

• Table 9-3: Cell, Gene, and RNA Therapy Market Summary, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
• Figure 9-2: Cell, Gene, and RNA Therapy Market Summary, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
• Figure 9-3: Cell and Gene Therapy Market, Distribution of Sales, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023

Cell vs. Gene Therapy Markets

• Table 9-4: Cell, Gene, & RNA Therapy Market Summary, by Method (Gene/CBG Therapy, RNA Therapy, Non-GM Cell Therapy), 2023-2029 ($ millions)
• Figure 9-4: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method (Gene/CBG Therapy, RNA Therapy, Non-GM Cell Therapy), 2023 (%)

Regional Market Overview

• Table 9-5: Cell, Gene, & RNA Therapy Market Summary, by Geographical Region (Europe, United States, Other Countries), 2023-2029 ($ millions)

United States

• Table 9-6: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
• Figure 9-5: U.S. Cell and Gene Therapy Market, Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
• Table 9-7: Major Cell and Gene Therapy Product Approvals, FDA

Europe/European Union

• Table 9-8: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
• Figure 9-6: Europe Cell and Gene Therapy Market Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
• Table 9-9: Major Cell and Gene Therapy Approvals by EMA

Other Countries

• Table 9-10: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029  ($ millions)
• Figure 9-7: ROW Cell, Gene, & RNA Therapy Market Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
• Table 9-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities

Competitor Ranking in Cell and Gene Therapy Markets

• Table 9-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2023 Sales ($ millions)
• Figure 9-8: Cell and Gene Therapy Market Share Estimates, 2023

 

Chapter 10: Market Participants

Leading Influencers

AlloSource

• Table 10-1: AlloSource Corporate Summary

Company Summary

Products

Alnylam Pharmaceuticals, Inc.

• Table 10-2: Alnylam Pharmaceuticals Corporate Summary

Company Summary

Products

Amgen

• Table 10-3: Amgen Corporate Summary

Company Summary

Products

AnGes Inc.

• Table 10-4: AnGes Corporate Summary

Company Summary

Products

Anterogen Co Ltd.

• Table 10-5: Anterogen Corporate Summary

Company Summary

Products

Atara Biotherapeutics

• Table 10-6: Atara Biotherapeutics Corporate Summary

Company Summary

Products

Athersys, Inc

• Table 10-7: Athersys Corporate Summary

Company Summary

Products

BioCardia

• Table 10-8: BioCardia Summary

Company Summary

Products

Biogen, Inc.

• Table 10-9: Biogen Corporate Summary

Company Summary

Products

BioMarin Pharmaceuticals

• Table 10-10: BioMarin Pharmaceuticals Corporate Summary

Company Summary

Products

bluebird bio, Inc.

• Table 10-11: bluebird bio Corporate Summary

Company Summary

Products

BrainStorm Cell Therapeutics

• Table 10-12: BrainStorm Cell Therapeutics Corporate Summary

Company Summary

Products

Bristol-Myers Squibb

• Table 10-13: Bristol-Myers Squibb Corporate Summary

Company Summary

Products

Candel Therapeutics

• Table 10-14: Candel Therapeutics Corporate Summary

Company Summary

Products

Castle Creek Biosciences

• Table 10-15: Castle Creek Corporate Summary

Company Summary

Products

Celyad Oncology

• Table 10-16: Celyad Oncology Corporate Summary

Company Summary

Products

Cook Myosite, Inc

• Table 10-17: Cook Myosite Corporate Summary

Company Summary

Products

Dendreon Pharmaceuticals (Sanpower)

• Table 10-18: Dendreon Corporate Summary

Company Summary

Products

FerGene, Inc (Ferring Pharmaceuticals)

• Table 10-19: FerGene Corporate Summary

Company Summary

Products

Gamida Cell Ltd.

• Table 10-20: Gamida Cell Corporate Summary

Company Summary

Products

GenSight Biologics S.A.

• Table 10-21: GenSight Biologics Corporate Summary

Company Summary

Products

Gilead Sciences, Inc.

• Table 10-22: Gilead Sciences Corporate Summary

Company Summary

Products

Gradalis, Inc

• Table 10-23: Gradalis Corporate Summary

Company Summary

Products

Helixmith

• Table 10-24: Helixmith Corporate Summary

Company Summary

Products

Inovio Pharmaceuticals, Inc.

• Table 10-25: Inovio Pharmaceuticals Corporate Summary

Company Summary

Products

Kiadis Pharma B.V. (Sanofi)

• Table 10-26: Kiadis Pharma Corporate Summary

Company Summary

Products

Medeor Therapeutics

• Table 10-27: Medeor Therapeutics Corporate Summary

Company Summary

Products

MEDIPOST Co, Ltd.

• Table 10-28: MEDIPOST Corporate Summary

Company Summary

Products

MeiraGTx

• Table 10-29: MeiraGTxCorporate Summary

Company Summary

Products

Mesoblast Ltd.

• Table 10-30: Mesoblast Corporate Summary

Company Summary

Products

Northwest Biotherapeutics, Inc.

• Table 10-31: Northwest Biotherapeutics Corporate Summary

Company Summary

Products

Novartis AG

• Table 10-32: Novartis Corporate Summary

Company Summary

Products

NuVasive Biologics

• Table 10-33: NuVasive Biologics Corporate Summary

Company Summary

Products

Orchard Therapeutics

• Table 10-34: Orchard Therapeutics Corporate Summary

Company Summary

Products

Organogenesis

• Table 10-35: Organogenesis Corporate Summary

Company Summary

Products

Orthofix

• Table 10-36: Orthofix Corporate Summary

Company Summary

Products

Osiris Therapeutics, Inc. (part of Smith & Nephew)

• Table 10-37: Osiris Corporate Summary

Company Summary

Products

Pharmicell

• Table 10-38: Pharmicell Corporate Summary

Company Summary

Products

Pluristem Therapeutics, Inc.

• Table 10-39: Pluristem Therapeutics Corporate Summary

Company Summary

Products

Sangamo Therapeutics

• Table 10-40: Sangamo Therapeutics Corporate Summary

Company Summary

Products

Sanofi

• Table 10-41: Sanofi Corporate Summary

Company Summary

Products

Sarepta

• Table 10-42: Sarepta Corporate Summary

Company Summary

Products

Sotio a.s.

• Table 10-43: Sotio Corporate Summary

Company Summary

Products

Spark Therapeutics

• Table 10-44: Spark Therapeutics Corporate Summary

Company Summary

Products

Tessa Therapeutics, Ltd.

• Table 10-45: Tessa Therapeutics Corporate Summary

Company Summary

Products

uniQure N.V.

• Table 10-46: UniQure Corporate Summary

Company Summary

Products

Vericel Corporation

• Table 10-47: Vericel Corporate Summary

Company Summary

Products